Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3321-3330 Newer>

Pharmaceutical Executive December 1, 2006 Jill Wechsler	Washington Report: The New Agenda Democrats are back on top in Congress after more than a decade as underdogs. The new leaders are mapping out a broad agenda with drug pricing and access high on the list.
Pharmaceutical Executive December 1, 2006 Sarah Houlton	Global Report: Not So NICE A new manifesto by the Association of the British Pharmaceutical Industry is designed to improve drug access in the UK, where industry has worried for years about poor uptake of new medicines.
Pharmaceutical Executive December 1, 2006	Thoughtleader: Thomas Ebeling, Novartis The Next Big Thing: An interview with the pharma's CEO, who has witnessed tremendous financial and scientific growth at the company and is on the brink of his next major milestone.
Pharmaceutical Executive December 1, 2006 Brown & Yacano	Legal: E-headache Document production has always been a tedious and costly part of litigation. Now, with new rules governing electronic information, pharma companies must brace for a whole new set of associated costs.
Pharmaceutical Executive December 1, 2006 Marcee Nelson	Direct to Consumer: Don't Wait By stocking waiting rooms with educational drug information, pharma can help get doctor-patient communication off on the right foot.
Pharmaceutical Executive December 1, 2006 Amin & Estrella	Alternative Media: Health on Demand Targeted video-on-demand offers pharma an entertaining new way to reach consumers.
Pharmaceutical Executive December 1, 2006 Ragnar Lofstedt	Back Page: The Post-Trust World People no longer put their faith in industry or regulators. What can we do about that? A good start would be understanding the human side of risk.
Pharmaceutical Executive December 1, 2006 White & Macchio	Marketing to Professionals: Fax Me! Don't throw away that machine just yet. All docs haven't switched to e-mail.
CFO December 1, 2006 Kate O'Sullivan	Biotech Dreaming Cities and states in the U.S. are vying to become biotechnology hot spots. Ultimately, some regions may not have enough of the key ingredients for biotech success.
Managed Care November 2006 Maureen Glabman	Genetic Testing: Major Opportunity, Major Problems Whether a person is likely to develop diabetes, cancer, schizophrenia, or stroke will be reasonably well predicted, and tests can also determine whether a patient will respond to a given therapy. That's the good part.
<Older 3321-3330 Newer> Return to current articles.